The warrant exercise provides near-term cash but adds roughly 17.7 million shares to the float, diluting existing holders. Monitor the company's cash runway and progress toward the PDS0301 Phase 3 trial initiation, as the $3.9 million combined with the September 2026 private placement proceeds will fund development.
Drugs in focus
PDSB drug pipeline →PDS0301
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Next catalyst
- None dated
What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $1.03entry
- T+1 · 6d ago −0.97%α −2.29% · $1.02
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology announced that NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, generating approximately $3.9 million in gross proceeds. The warrants were issued in connection with a September 2026 private placement that raised $11.3 million. Proceeds will fund advancement of PDS0301 toward a Phase 3 trial and partnership strategy for PDS0101.
Key Facts
- NantWorks exercised warrants to purchase 17,699,115 shares at $0.22 per share
- Gross proceeds to PDS Biotechnology were approximately $3.9 million
- Warrants were issued in connection with a September 14, 2026 private placement that raised $11.3 million
- Proceeds will support advancement of PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and partnership strategy for PDS0101
- Warrants are subject to a 19.9% beneficial ownership limitation; excess exercised for pre-funded warrants at $0.00033 per share
- Company market cap is $129 million; the 17.7 million shares represent significant dilution relative to current shares outstanding
Financial Impact
Gross proceeds of approximately $3.9 million from warrant exercise; 17,699,115 shares issued at $0.22 per share
Risk Factors
- Significant dilution from the issuance of 17.7 million shares at a low exercise price
- Clinical-stage biotech with no approved products; reliance on additional financing to fund operations
- Proceeds may be insufficient to fully fund Phase 3 trial for PDS0301
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-042898 |
| Document: ef20085268_ex99-1.htm | 0001140361-26-042898 |
| Document: 0001140361-26-042898-index-headers.html | 0001140361-26-042898 |
| Document: 0001140361-26-042898-index.html | 0001140361-26-042898 |
| Document: 0001140361-26-042898.txt | 0001140361-26-042898 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers